NASDAQ:IMMU Investor Alert: Investigation over Potential Wrongdoing at Immunomedics, Inc

By , in PR PR California on .

San Diego, CA — 12/19/2017 — An investigation was announced for investors in shares of Immunomedics, Inc. (NASDAQ:IMMU) was announced over potential breaches of fiduciary duties by certain officers and directors at Immunomedics.

Investors who purchased shares of Immunomedics, Inc. (NASDAQ:IMMU) and currently hold any of those NASDAQ:IMMU shares have certain options and should contact the Shareholders Foundation at [email protected] or call 858-779-1554.

The investigation by a law firm concerns whether certain Immunomedics directors breached their fiduciary duties and caused damage to the company and its shareholders.

Morris Plains, NJ based Immunomedics, Inc. is a clinical-stage biopharmaceutical company. Immunomedics, Inc. reported that Total Revenue declined from $3.23 million for the 12 months period that ended on June 30, 2016 to $3.09 million for the 12 months period that ended on June 30, 2017 and that its Net Loss increased over those time periods from $59.04 million to $153.21 million.

Shares of Immunomedics, Inc. (NASDAQ:IMMU) closed on December 18, 2017 at $12.69 per share.

Those who purchased shares of Immunomedics, Inc. (NASDAQ:IMMU), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
[email protected]

The following two tabs change content below.
Sarah Thompson

Sarah Thompson

Sarah is a financial reporter, focusing on technology, national security, and policing. Before joining Daily Telescope she worked as a staff writer at Fast Company and spent two years as a foreign correspondent in Turkey. Her work has been published in Al Jazeera America, The Nation, Vice News, Motherboard, and many other outlets.
%d bloggers like this: